Deutsche Bank Ag\ Salarius Pharmaceuticals, Inc. Transaction History

Deutsche Bank Ag\

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 11, 2021	SELL	$1.02 - $1.52 $204 - $304	-200 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$1.0 - $3.0 $200 - $600	200 New	200 $0
Q3 2020 Nov 12, 2020	SELL	$0.77 - $1.52 $1,255 - $2,477	-1,630 Closed	0 $0
Q2 2020 Aug 13, 2020	SELL	$0.6 - $1.82 $8,101 - $24,575	-13,503 Reduced 89.23%	1,630 $2,000
Q1 2020 May 14, 2020	BUY	$0.56 - $3.82 $8,474 - $57,808	15,133 New	15,133 $10,000

Ticker SLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,244,650
Market Cap $3.25M
Description
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a ...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.